BlinkLab Limited (ASX:BB1)

Australia · Delayed Price · Currency is AUD

0.6350

+0.0250 (4.10%)

Sep 30, 2026, 9:59 AM AEST

Market Cap	97.32M +48.0%
Revenue (ttm)	1.21M +221.5%
Net Income	-7.22M
EPS	-0.06
Shares Out	153.26M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	32,271
Open	0.6300
Previous Close	0.6100
Day's Range	0.6300 - 0.6350
52-Week Range	0.5100 - 1.1050
Beta	1.34
Analysts	Buy
Price Target	2.24 (+252.76%)
Est. Earnings	Nov 25, 2026

About BlinkLab

BlinkLab Limited focuses on the development and commercialization of intellectual property related to smartphone-based neurobehavioural testing. Its smartphone-based application serves as a device for conducting neurobehavioral evaluations and objective sensorimotor biomarkers, which provides scientific support for future regulatory approval and clinical adoption. The company’s application also enables remote and rapid testing to aid research on neurodevelopmental and neurodegenerative conditions such as schizophrenia, autism, attention deficit... [Read more]

Industry Health Information Services

Sector Healthcare

Founded 2021

Country Australia

Stock Exchange Australian Securities Exchange

Ticker Symbol BB1

Full Company Profile

Financial Performance

In fiscal year 2026, BlinkLab's revenue was 1.21 million, an increase of 221.54% compared to the previous year's 375,551. Losses were -7.22 million, 26.5% more than in 2025.

Financial Statements

Analyst Summary

According to 2 analysts, the average rating for BB1 stock is "Buy." The 12-month stock price target is $2.24, which is an increase of 252.76% from the latest price.

Price Target

$2.24

(252.76% upside)

Analyst Consensus: Buy

Stock Forecasts